Cytokinetics公司出价650万可兑换纸条, 提议为旧债再融资, 降低利息, 支持药物启动。 Cytokinetics priced a $650M convertible note offering to refinance older debt, lower interest, and support drug launch.

Cytokinetics 宣布发行 6.5 亿美元的可转换优先票据的定价，该票据将于 2031 年到期，高于最初的 5.5 亿美元计划，用于为其 2027 年可转换票据再融资。 Cytokinetics announced the pricing of a $650 million offering of convertible senior notes due in 2031, up from an initial $550 million plan, to refinance its 2027 convertible notes. 新纸币的年利率为1.75%,贴现券比前纸币低,兑换价约68.42美元。 The new notes carry a 1.75% annual interest rate, a lower coupon than the prior notes, and feature a higher conversion price of about $68.42. 收益将支持可能的商业启动Aficamten公司的一般需求,并可能留存其余的2027笔票据。 Proceeds will support the potential commercial launch of aficamten, general corporate needs, and possibly retire remaining 2027 notes. 这项提议定于2025年9月19日结束,其中包括承保人可选择再购买多达1亿美元的资金。 The offering, set to close on September 19, 2025, includes an option for underwriters to buy up to $100 million more. 附注是高级债务,无担保债务,利息每半年支付一次。 The notes are senior, unsecured obligations, with interest paid semi-annually.